Molly Chiaramonte

Corporate Officer/Principal chez

RP Management LLC

Finance

Consumer Services

Health Technology

Profil

Molly Chiaramonte is currently working as the Vice President-Research & Investments at RP Management LLC since 2011.
Prior to this, she worked as a Senior Vice President-Research & Investments at Royalty Pharma Plc from 2008 to 2021.
Before that, Molly was a Research Associate at Jefferies LLC from 2006 to 2008.
She completed her undergraduate degree at Providence College and holds graduate and doctorate degrees from The University of Colorado.

Postes actifs de Molly Chiaramonte

Sociétés	Poste	Début
RP Management LLC RP Management LLC Financial ConglomeratesFinance Provides biopharma royalty transactions services	Corporate Officer/Principal	23/11/2011

Tous les postes actifs de Molly Chiaramonte

Anciens postes connus de Molly Chiaramonte

Sociétés	Poste	Fin
ROYALTY PHARMA PLC	Corporate Officer/Principal	01/06/2021
Jefferies LLC Jefferies LLC Investment Banks/BrokersFinance Provides brokerage services	Analyst-Equity	30/04/2008

Voir l'expérience en détail de Molly Chiaramonte

Formation de Molly Chiaramonte

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Molly Chiaramonte

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	5
Jefferies LLC Jefferies LLC Investment Banks/BrokersFinance Provides brokerage services	Finance
Providence College Providence College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The University of Colorado The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
RP Management LLC RP Management LLC Financial ConglomeratesFinance Provides biopharma royalty transactions services	Finance
Royalty Pharma Plc Royalty Pharma Plc Pharmaceuticals: MajorHealth Technology Buys and operates a portfolio of biopharmaceutical royalties	Health Technology